NASDAQ · TLPH
Talphera, Inc.
$1.05-$0.02 (-1.87%)
Talphera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.12% below the high.
Loading market information…
NASDAQ · PMD · USD
Stock price, dividends, earnings
Quote as of Feb 10, 2026, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Psychemedics Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Psychemedics Corporation’s forward annual dividend is $0.28 per share, paid quarterly. The forward yield is 10.49% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Psychemedics Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.05-$0.02 (-1.87%)
Talphera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.12% below the high.
$0.70-$0.00 (-0.16%)
Enzo Biochem, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.27% below the high.
$0.46+$0.00 (+0.22%)
Chembio Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.31% below the high.
$0.14$0.00 (0.0%)
Titan Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.33% below the high.
$0.73-$0.03 (-3.84%)
Anew Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.79% below the high.
$0.61+$0.61 (+100.0%)
23andMe Holding Co.’s quoted price sits in the lower half of its reported 52-week range, 95.25% below the high.
$0.18-$0.01 (-5.51%)
Theriva Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.09% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
